CK Life Sciences' Two Cancer Vaccines Selected for Presentation at US SITC Meeting

On 4 November 2026, the South China Morning Post business section reported that Sequencio Therapeutics, under Li Ka-shing's CK Life Sciences, had its two cancer vaccine candidates CKLS118 and CKLS202 selected for presentation of preclinical data on Friday at the Society for Immunotherapy of Cancer (SITC) meeting in Phoenix, Arizona. The company said it will present the relevant research findings at the meeting. The report did not mention specific research data, clinical stage or subsequent development plans for the two vaccine candidates. The current progress of the event is that they have been selected for presentation of preclinical data at the SITC meeting, and the company will present the research findings there.

Generated by AI from reporting · updated 2 hours ago

There are not enough continuous observations to draw a trend yet.